| Statement |
1.Date of the shareholders meeting resolution:2025/06/26
2.Name and title of the director with permission to engage in competitive
conduct:
Director:Fu Hui-Tung
Director:Chang Ming-Cheng
Director:Hsieh Yen-Sheng
Director:Excelsior Group Holdings Co., Ltd. Representative:Chen Tun-Ling
Director:Excelsior Group Holdings Co., Ltd. Representative:Chang Hsien-Cheng
Director:Fu Jo-Hsuan
Independent director:Chan,Chien-Lung
Independent director:Kuo,Ming-Yi
Independent director:Huang,Chung-Chen
3.Items of competitive conduct in which the director is permitted to engage:
Concurrently serve as a director with the same or similar business scope
as the Company.
4.Period of permission to engage in the competitive conduct:
A director's term of office
5.Circumstances of the resolution (please describe the results of voting in
accordance with Article 209 of the Company Act):
The resolution was adopted by a majority of the shareholders presented at
the general meeting who represented two-thirds or more of the total number
of shares represented by the attending shareholders.
6.If the permitted competitive conduct belongs to the operator of a mainland
China area enterprise, the name and title of the directors
(if it is not the operator of a Mainland-area enterprise, please enter
“N/A” below):
Director:Chang Ming-Cheng
Director:Fu Jo-Hsuan
7.Company name of the mainland China area enterprise and the director's
position in the enterprise:
Director:Chang Ming-Cheng，Director of SinoExcelsior Investment
Incorporation.
Director:Fu Jo-Hsuan，Director of SinoExcelsior Investment Incorporation.
8.Address of the mainland China area enterprise:
SinoExcelsior Investment Incorporation address:
Room 301-2, No.1089, Kang Ning Road, Shanghai,China
9.Operations of the mainland China area enterprise:
SinoExcelsior Investment Incorporation:Enterprise management consulting,
Sales of Class I medical devices, Import and export of goods, Import and
export of technology, Internet sales (excluding goods requiring licensing),
Sales agency services, Health consultation services (excluding medical
diagnosis and treatment services),Information consulting services (excluding
licensed information consulting services), Technical services, technical
development, technical consulting, technical exchange, technology transfer,
and technology promotion, Marketing planning, Wholesale of cosmetics.
(Except for projects that require approval according to the law, the company
shall independently carry out business activities in accordance with the
business license)
10.Impact on the company's finance and business:None.
11.If the directors have invested in the mainland China area enterprise,
the monetary amount of the investment and their shareholding ratio:None.
12.Any other matters that need to be specified:None.
|
